Kaplan Andrew, Fournier Alyson E
Department of Neurology and Neurosurgery, Montréal Neurological Institute, McGill University, Montréal, Québec, Canada.
Neural Regen Res. 2017 Jul;12(7):1040-1043. doi: 10.4103/1673-5374.211176.
The goal of developing treatments for central nervous system (CNS) injuries is becoming more attainable with the recent identification of various drugs that can repair damaged axons. These discoveries have stemmed from screening efforts, large expression datasets and an improved understanding of the cellular and molecular biology underlying axon growth. It will be important to continue searching for new compounds that can induce axon repair. Here we describe how a family of adaptor proteins called 14-3-3s can be targeted using small molecule drugs to enhance axon outgrowth and regeneration. 14-3-3s bind to many functionally diverse client proteins to regulate their functions. We highlight the recent discovery of the axon-growth promoting activity of fusicoccin-A, a fungus-derived small molecule that stabilizes 14-3-3 interactions with their client proteins. Here we discuss how fusicoccin-A could serve as a starting point for the development of drugs to induce CNS repair.
随着最近发现各种能够修复受损轴突的药物,开发中枢神经系统(CNS)损伤治疗方法的目标变得越来越可行。这些发现源于筛选工作、大型表达数据集以及对轴突生长背后的细胞和分子生物学的深入理解。继续寻找能够诱导轴突修复的新化合物将非常重要。在这里,我们描述了如何使用小分子药物靶向一类称为14-3-3的衔接蛋白家族,以增强轴突生长和再生。14-3-3与许多功能多样的客户蛋白结合以调节它们的功能。我们强调了最近发现的藤霉素A促进轴突生长的活性,藤霉素A是一种源自真菌的小分子,可稳定14-3-3与其客户蛋白的相互作用。在这里,我们讨论藤霉素A如何作为开发诱导中枢神经系统修复药物的起点。